Isolation and Characterization of an HLA-DPB1*04:01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy-Reference-Cited by-同舟云学术

Isolation and Characterization of an HLA-DPB1*04:01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy

Published:2016-06 Issue:5 Volume:39 Page:191-201
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Yao Xin,Lu Yong-Chen,Parker Linda L.,Li Yong F.,El-Gamil Mona,Black Mary A.,Xu Hui,Feldman Steven A.,van der Bruggen Pierre,Rosenberg Steven A.,Robbins Paul F.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference59 articles.

1. Adoptive cell transfer as personalized immunotherapy for human cancer;Rosenberg;Science,2015

2. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response;Robbins;Clin Cancer Res,2015

3. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1;Robbins;J Clin Oncol,2011

4. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma;Rapoport;Nat Med,2015

5. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19;Kochenderfer;Blood,2010

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model;Journal of Clinical Investigation;2024-02-27

2. Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors;Nature Immunology;2023-07-03

3. Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors;Frontiers in Immunology;2023-05-23

4. The Melanoma-Associated Antigen Family A (MAGE-A): A Promising Target for Cancer Immunotherapy?;Cancers;2023-03-15

5. Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer;Theranostics;2023